期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 117, 期 3, 页码 571-575出版社
SPRINGER
DOI: 10.1007/s10549-009-0309-1
关键词
Breast cancer; Tamoxifen; CYP2D6; Hot flash; Genotype
类别
资金
- Pharmacogenetics Research Network [U-01 GM61373]
- Consortium on Breast Cancer Pharmacogenomics (COBRA)
- National Institutes of Health Clinical Pharmacology [T32-GM08425]
- National Institute of General Medical Sciences
- National Institutes of Health [K24RR020815]
- Damon Runyon Cancer Research Foundation
- Fashion Footwear Charitable Foundation of New York
- National Center for Research Resources (NCRR) [M01RR000042, M01-RR020359, M01-RR00750]
- National Institutes of Health (NIH)
Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据